Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Journal of Clinical Pharmacology
Jessie GuWilliam P Dole

Abstract

Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ696 caused dose-dependent increases in atrial natriuretic peptide immunoreactivity (due to NEP inhibition) in Sprague-Dawley rats and provided sustained, dose-dependent blood pressure reductions in hypertensive double-transgenic rats. In healthy participants, a randomized, double-blind, placebo-controlled study (n = 80) of single-dose (200-1200 mg) and multiple-dose (50-900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6-4.9 hours), AHU377 (0.5-1.1 hours), and its active moiety, LBQ657 (1.8-3.5 hours). LCZ696 treatment was associated with increases in plasma cGMP, renin concentration and activity, and angiotensin II, providing evidence for NEP inhibition and angiotensin receptor blockade. In a randomized, open-label crossover study in healthy participants (n = 56), oral LCZ696 400 mg and valsartan 320 mg were shown to provide similar exposure to val...Continue Reading

References

May 12, 1995·Journal of Medicinal Chemistry·G M KsanderA Trapani
Jan 1, 1997·Hypertension·J BohlenderD Ganten
Sep 13, 2003·British Journal of Clinical Pharmacology·Wei-Chi LiaoHoward Uderman
Feb 14, 2004·Basic Research in Cardiology·Gary F Baxter
Mar 24, 2006·Expert Opinion on Pharmacotherapy·Nisha B MistrySverre E Kjeldsen
Apr 19, 2007·Heart Failure Reviews·Candace Y W Lee, John C Burnett
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Michel AziziAlessandra Bura-Rivière

❮ Previous
Next ❯

Citations

Nov 4, 2010·Current Hypertension Reports·Julian Segura, Luis M Ruilope
Aug 6, 2013·Drugs & Aging·Kannayiram AlagiakrishnanWilbert S Aronow
May 24, 2011·Current Opinion in Pediatrics·Anne M Lenz
Feb 11, 2014·Current Atherosclerosis Reports·J GeorgeC C Lang
Nov 15, 2013·European Heart Journal·Massimo VolpeJohn Burnett
Nov 16, 2013·Current Heart Failure Reports·Archyut ValluriChim C Lang
May 6, 2014·Pflügers Archiv : European journal of physiology·Soidjon D KhodjaevFady I Malik
Jul 1, 2014·Heart Failure Clinics·Jose Nativi-NicolauJames C Fang
Dec 12, 2012·Cardiovascular Drugs and Therapy·Thomas G von Lueder, Henry Krum
Jun 25, 2013·Pharmacology & Therapeutics·Dimitrios M KonstantinouGeorge D Giannoglou
Dec 8, 2015·Expert Review of Cardiovascular Therapy·Mauro Gori, Michele Senni
Jun 5, 2013·Expert Opinion on Investigational Drugs·Julian SeguraLuis M Ruilope
Sep 13, 2011·Expert Opinion on Emerging Drugs·Ulrike Muscha SteckelingsMichael Bader
May 15, 2013·Expert Opinion on Investigational Drugs·Adriaan A VoorsPeter van der Meer
Sep 13, 2014·International Journal of Cardiology·Massimo Volpe
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Vasiliki KatsiIoannis Kallikazaros
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Aug 19, 2015·Basic & Clinical Pharmacology & Toxicology·Mathilde Borring AndersenDaniela Grimm
Dec 25, 2012·The American Journal of Medicine·Stanley S LiuKapil Parakh
Jan 16, 2016·The Korean Journal of Internal Medicine·Shir Lynn Lim, Carolyn Su Ping Lam
Jun 16, 2015·Journal of Clinical Pharmacology·Lu GanGangadhar Sunkara
Mar 1, 2016·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·Á KovácsN Hamdani
Feb 14, 2016·Expert Review of Clinical Pharmacology·Spyridon KatsanosJohn T Parissis
Jan 29, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jian ShiHao-Jie Zhu
Mar 5, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jimmy FlarakosJames B Mangold
Apr 4, 2016·Trends in Cardiovascular Medicine·Jonathan S Gordin, Gregg C Fonarow
Sep 14, 2016·Hospital Pharmacy·Dennis J CadaJames Leonard
Sep 26, 2015·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Claudio BorghiUNKNOWN SIF Task Force
Dec 1, 2015·Frontiers in Pharmacology·Silvio WeberAli El-Armouche
Mar 11, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Yi HanGangadhar Sunkara
Oct 16, 2015·Current Heart Failure Reports·Jared Mills, Orly Vardeny
Nov 30, 2012·European Journal of Heart Failure·Dirk J van Veldhuisen, John J V McMurray
Mar 11, 2015·European Journal of Heart Failure·John J V McMurray
Apr 15, 2016·International Journal of Cardiology·Vincenzo MollaceFrancesco Rossi
May 20, 2014·Pharmacology & Therapeutics·Thomas G von LuederHenry Krum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.